Treatment characteristics of study subjects
| Visit A (n = 20)* | Visit B (n = 20)* | |
|---|---|---|
| *Visit A: premedication with inhaled salbutamol 400 µg pMDI; visit B: premedication with inhaled salbutamol 400 µg pMDI + nebulised salbutamol 1500 µg. | ||
| Short acting β2 agonists (puffs/week) | 16 (0–70) | 14 (0–64) |
| Treated with long acting β2 agonists (n) | 11 | 11 |
| Treated with inhaled corticosteroids (n) | 16 | 16 |
| Treated with theophylline (n) | 1 | 1 |
| Treated with oral corticosteroids (n) | 2 | 2 |
| No controller medication (n) | 3 | 3 |